Title: Differentiating agents in malignant disease
Abstract: Medical and Pediatric OncologyVolume 19, Issue 2 p. 71-83 Review Article Differentiating agents in malignant disease Daniel G. Bruetman MD, Daniel G. Bruetman MD Section of Medical Oncology, Department of Internal Medicine, Rush-Presbyterian-St. Luke's Medical Center, Chicago, IllinoisSearch for more papers by this authorJules E. Harris MD, Jules E. Harris MD Section of Medical Oncology, Department of Internal Medicine, Rush-Presbyterian-St. Luke's Medical Center, Chicago, IllinoisSearch for more papers by this authorKenning M. Anderson MD PhD, Corresponding Author Kenning M. Anderson MD PhD Section of Medical Oncology, Department of Internal Medicine, Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois Department of Biochemistry, Rush-Presbyterian-St. Luke's Medical Center, Chicago, IllinoisSection of Medical Oncology, 1725 W. Harrison Street. Suite 830, Chicago, IL 60612Search for more papers by this author Daniel G. Bruetman MD, Daniel G. Bruetman MD Section of Medical Oncology, Department of Internal Medicine, Rush-Presbyterian-St. Luke's Medical Center, Chicago, IllinoisSearch for more papers by this authorJules E. Harris MD, Jules E. Harris MD Section of Medical Oncology, Department of Internal Medicine, Rush-Presbyterian-St. Luke's Medical Center, Chicago, IllinoisSearch for more papers by this authorKenning M. Anderson MD PhD, Corresponding Author Kenning M. Anderson MD PhD Section of Medical Oncology, Department of Internal Medicine, Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois Department of Biochemistry, Rush-Presbyterian-St. Luke's Medical Center, Chicago, IllinoisSection of Medical Oncology, 1725 W. Harrison Street. Suite 830, Chicago, IL 60612Search for more papers by this author First published: 1991 https://doi.org/10.1002/mpo.2950190202AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Seifter EJ, Levitt ML, Kramer BS: An outlier theory of cancer curability: Tumor cell differentiation as a therapeutic goal. Am J Med 83: 757–760, 1987. 2 Reiss M, Gamba-Vitalo C, Sartorelli AC: Induction of tumor cell differentiation as a therapeutic approach: Preclinical models for hematopoietic and solid neoplasms. Cancer Treat Rep 70: 201–218, 1986. 3 Pierce GB, Wallace C: Differentiation of malignant to benign cells. Cancer Res 31: 127–134, 1971. 4 Block A: Growth and differentiation signals as determinants of cancer cell proliferation. Adv Enzyme Regul 28: 359–374. 1989. 5 Pierce GB: Tumors as caricatures of the process of tissue renewal: Prospects for therapy by directing differentiation. Cancer Res 48: 1996–2004, 1988. 6 Sachs L: Cell differentiation and bypassing of genetic defects in the suppression of malignancy. Cancer Res 47: 1981–1986, 1987. 7 Waxman S. Scher W. Scher BM: Basic principles for utilizing combination differentiation agents. Cancer Detect Prev 9: 395–407. 1986. 8 Tzen CY, Estervig DN, Minoo P, Filipak M, Maercklein PB, Hoerl BJ, Scott RE: Differentiation, cancer and anticancer activity. Biochem Cell Biol 66: 478–489, 1988. 9 Marks PA, Sheffery M, Ramsay R, Ikeda K, Rifkind RA: Induction of transformed cells to terminal differentiation. Ann NY Acad Sci 511: 246–255, 1987. 10 Schwartz EL, Wiernik PH: Differentiation of leukemic cells by chemotherapeutic agents. J Clin Pharmacol 28: 779–794, 1988. 11 Illmensee K, Mintz B: Totipotency and normal differentiation of single teratocarcinoma cells cloned by injection into blastocysts. Proc Natl Acad Sci USA 73: 548–553, 1976. 12 Gootwine E, Webb CJ, Sachs L: Participation of myeloid leukaemic cells injected into embryos in haematopoietic differentiation in adult mice. Nature 299: 63–65, 1982. 13 Jacobson RJ, Twenple MJ, Singer JW, et al.: A clonal complete remission in a patient with acute nonlymphocytic leukemia originating in a multipotent stem cell. N Engl J Med 310: 1513–1517. 1984. 14 Fearon ER, Burke PJ, Schiffer CA, et al.: Differentiation of leukemic cells to polymorphonuclear leukocytes in patients with acute nonlymphocytic leukemia. N Engl J Med 315: 15–24, 1986. 15 Ondrey F, Anderson KA, Hoeltgen D, Harris JE: Differentiation of U937 cells by 5,8,11,14-Eicosatetraynoic acid, a competitive inhibitor of arachidonic acid metabolism. Exp Cell Res 179: 477–487, 1988. 16 Eisenstein BI: The polymerase chain reaction. N Engl J Med 322: 178–183, 1990. 17 Cline MJ, Slamon DJ, Lipsick JS: Oncogenes: Implications for the diagnosis and treatment of cancer. Ann Intern Med 101: 223–233, 1984. 18 Bruetman D, Iyer A, Anderson KA, Ondrey F, Harris JE: Down regulation of c-Myc by ETYA (5,8,11,14-Eicosatetraynoid acid), a competitive inhibitor of arachidonic acid metabolism. Proc Am Assoc Cancer Res 30: 432, 1989. 19 Klein G: The approaching era of the tumor suppressor genes. Science 238: 1538–1545, 1987. 20 Rovera G, O'brien TG, Diamond L: Induction of differentiation of human promyelocytic leukemic cells by tumor promoters. Science 204: 868–870, 1979. 21 Stone RM, Weber BL, Spriggs DR, Kufe DW: Phospholipase C activates protein kinase C and induces monocytic differentiation of HL60 cells. Blood 72: 739–744, 1988. 22 Brelvi ZS, Christakos S, Studzinski GP: Expression of monocyte specific oncogenes c-Fos and c-Fms in HL60 cells treated with vitamin D3 analogs correlates with inhibition of DNA synthesis and reduced calmodulin concentrations. Lab Invest 55: 269–275, 1986. 23 Friend C, Scher W, Holland JG, Sato T: Hemoglobin synthesis in murine virus induced leukemic cells in vitro: Stimulation of erythroid differentiation by dimethyl sulfoxide. Proc Natl Acad Sci USA 68: 378–382, 1971. 24 Dmitrusky E, Kuehl WM, Hollis GF, et al.: Expression of a transfected human c-Myc oncogene inhibits differentiation of a mouse erythroleukaemia cell line. Nature 322: 748–750, 1986. 25 Prochownik EV, Kukowska J: Deregulated expression of c-Myc by murine erythroleukaemia cells prevents differentiation. Nature 322: 848–850, 1986. 26 Schwartz EL, Mahler AM: Enhanced mutagenic responsiveness to granulocyte-Macrophage colony stimulating factor in HL60 promyelocytic leukemia cells upon induction of differentiation. Cancer Res 48: 2683–2687, 1988. 27 Smithgall TE, Yo G, Glazer RI: Identification of the differentiation associated p93 tyrosine protein kinase of HL60 leukemia cells as the product of the human c-Fes locus and its expression in myelomonocytic cells. J Biol Chem 263: 15050–15055, 1988. 28 Breitman TR, Selovick SE, Collins SJ: Induction of differentiation of the human promyelocytic leukemia cell line (hL60) by retinoic acid. Proc Natl Acad Sci USA 77: 2936–2940, 1980. 29 Collins SJ, Ruscetti FW, Gallagher RE, Gallo RC: Terminal differentiation of human promyelocytic leukemia cells induced by dimethyl sulfoxide and other polar compounds. Proc Natl Acad Sci USA 75: 2458–2462, 1978. 30 Imaizumi M, Vozumi J, Breitman TR: Retinoic acid induces monocytic differentiation of HL60/MRI, a cell line derived from a transplantable HL60 tumor. Cancer Res 47: 1434–1440, 1987. 31 Wickstrom EL, Bacon TA, Gonzalez A, et al.: Anti c-Myc DNA increases differentiation and decreases colony formation by HL60 cells. In Vitro Cell Dev Biol 24: 297–302, 1989. 32 Stein CA, Cohen JS: Antisense compounds: Potential role in cancer chemotherapy. Adv Oncol 1: 79–97, 1989. 33 Vander Krol AR, Mol JNM, Stuitze AR: Modulation of eukaryotic gene expression by complimentary RNA or DNA sequences. Biotechnology 6: 958–976, 1988. 34 Mikkelsen T, Cavenee WK: Suppressors of the malignant phenotype. Cell Growth Differ 1: 201–207, 1990. 35 Stanbridge EJ: A genetic basis for tumor suppression. Ciba Found Symp 142: 149–158, 1989. 36 Rous P: A sarcoma of the fowl transmissible by an agent separable from the tumor cells. J Exp Med 13: 397–411, 1911. 37 Collett MS, Erikson PL: Protein kinase activity associated with the avian sarcoma virus src gene product. Proc Natl Acad Sci USA 75: 2021–2024, 1978. 38 Vehara Y, Murakami Y, Mizuno S, Kawai S: Inhibition of transforming activity of tyrosine kinase oncogenes by herbimycin A. Virology 164: 294–298, 1988. 39 Vehara Y, Hori M, Takeuchi T, Umezawa H: Phenotypic change from transformed to normal induced by benzoquinonord anasmycins accompanies inactivation of p60 src in rat kidney cells infected with Rous sarcoma virus. Mol Cell Biol 6: 2198–2206, 1986. 40 Honma Y, Okabe-Kado J, Hozumi M, et al.: Induction of erythroid differentiation of K562 human leukemic cells by herbimicin A, an inhibitor of tyrosine kinase activity. Cancer Res 49: 331–334, 1989. 41 Lotan R, Abita JP: Membrane events associated with tumor cell differentiation: The status of differentiation therapy of cancer. Serono Symposia Publ 45: 127–148, 1988. 42 Carlson J, Dorey F, Cragoe F, Jr, Koeffler MP: Amiloride potentiation of differentiation of human promyelocytic cell line HL60. JNCI 72: 13–17, 1984. 43 Rozengurt E, Mendoza S: Monovalent influxes and the control of cell proliferation in cultured fibroblasts. Ann NY Acad Sci 339: 175–189, 1980. 44 Meeting report. The cell membrane and cell signals as targets in cancer chemotherapy. AACR, EORTC and BACR Special Conference. Cancer Res 50: 2203–2211, 1990. 45 Metcalfe JC, Moore JP, Smith GA, Hesketh TR: Calcium and cell proliferation. Br Med Bull 42: 405–412, 1986. 46 Boynton AL: Calcium and epithelial cell proliferation. Miner Electrolyte Metab 14: 86–94, 1988. 47 Evain D, Binet E, Anderson WB: Alterations in calcitonin and parathyroid hormone responsiveness of adenylate cyclase in F9 embryonal carcinoma cells treated with retinoic acid and dibutyryl cyclic AMP. J Cell Physiol 109: 453–459, 1981. 48 Thomas G. Chomienne C, Balitrand N, et al.: Granulocytic differentiation induced by retinoic acid in HL60 cells is associated with changes in adenylate cyclase activity. Anticancer Res 6: 857–860, 1986. 49 Girard PR, Stevens VL, Blackshear PJ, et al.: Immunocytochemical evidence for phorbol ester induced directional translocation of protein kinase C in HL60, CHO and E75KS cells: Possible role in differentiation. Cancer Res 47: 2892–2898, 1987. 50 Zick Y, Grunberger G, Rees-Jones RW, Comi RJ: Use of tyrosine containing polymers to characterize the substrate specificity of insulin and other hormone stimulated tyrosine kinases. Eur J Biochem 148: 177–182, 1985. 51 Morgan NG: “ Cell Signalling.” New York: The Guilford Press, 1989, pp 1–198. 52 Burck KB, Liu ET, Larrick JW: “ Oncogenes. An Introduction to the Concept of Cancer Genes.” New York: Springer-Verlag, 1988. pp 1–280. 53 Merrill AH: Lipid modulators of cell function. Nutr Rev 47: 161–169, 1989. 54 Del Rosso M, Pucci M, Fibbi G, Dini G: Interaction of urokinase with specific receptors abolishes the time of commitment to terminal differentiation of murine erythroleukaemia (friend) cells. Br J Haematol 66: 289–294, 1987. 55 Pommier CG, O'shea J, Chused T, et al.: Differentiation stimuli induce receptors for plasma fibronectin on the human myelomonocytic cell line, HL60. Blood 64: 858–866, 1984. 56 Flier JS, Underhill LH: The cellular basis of site specific tumor metastases. N Engl J Med 322: 605–612, 1990. 57 Todd III RF, Liu DY: Mononuclear phagocytic activation: Activation associated antigens. Fed Proc 45: 2829–2836, 1986. 58 Hattori T, Pack M, Bougnoux S, et al.: Interferon induced differentiation of U937 cells. J Clin Invest 72: 237–244, 1983. 59 Bagli DJ, Steele GD Jr, Barlozzari T: Natural killer sensitivity of colorectal carcinoma targets. Correlation with degree of differentiation. Arch Surg 124: 89–93, 1989. 60 Tsao D, Morita A, Bella A Jr, et al.: Differential effects of sodium butyrate, dimethyl sulfoxide, and retinoic acid on membrane associated antigens, enzymes and glycoproteins of human rectal adenocarcinoma cells. Cancer Res 42: 1052–1058, 1982. 61 Andrews PW, Trinchieri G, Peruggia B, et al.: Induction of class I major histocompatibility complex antigens in human teratocarcinoma cells by interferon without induction of differentiation, growth inhibition or resistance to viral infection. Cancer Res 47: 740–746, 1987. 62 Gastl G, Marth C, Leiter E, et al.: Effects of human recombinant alpha2-Interferon and γ-Interferon on human breast cancer cell lines: Dissociation of antiproliferative activity and induction of HLA-DR antigen expression. Cancer Res 45: 2957–2961, 1985. 63 Vogelstein B, Fearon ER, Hamilton SR, et al.: Genetic alterations during colorectal tumor development. N Engl J Med 319: 525–532, 1988. 64 Weisbart RH, Golde DW: Physiology of granulocyte and macrophage colony stimulating factors in host defense. Hematopoietic Growth Factors. Hum Oncol Clin North Am 3: 401–409, 1989. 65 Gabrilove JL (ed): Clinical applications of haematopoietic growth factors. Semin Hematol 26 (2): 1–23. 1989. 66 Moore MAS, Dexter TM: The role of hematopoietic growth factors in normal and leukemic cell differentiation: The status of differentiation therapy in cancer. Serono Symposia Publ 45: 201–213, 1988. 67 Gillio AP, Bonilla MA, O'reilly RJ, et al.: Effect of recombinant human G-CSF on hematopoietic reconstitution following autologous bone marrow transplantation in primates. Blood 68: 283a. 1986. 68 Souza L, Boone T, Gabrilove J, et al.: Recombinant human granulocyte colony stimulating factor: Effects on normal and leukemic myeloid cells. Science 232: 61–65, 1986. 69 Browder TM, Dunbar CE, Nienhuis AW: Private and public autocrine loops in neoplastic cells. Cancer Cell 1: 9–17, 1989. 70 Demetri GD, Griffin JD: Hemopoietins and leukemia. Hematopoietic Growth Factors. Hematol Oncol Clin North Am 3: 535–553, 1989. 71 Sherr CJ, Rettenmier SW, Sacca R, et al.: The c-Fms protooncogene product is related to the receptor for the mononuclear phagocyte growth factor, CSF-1. Cell 41: 665–676, 1985. 72 Wheeler EF, Rettenmier CW, Look AT, et al.: The v-Fms oncogene induces factor independence and tumorigenicity in CSF-1 dependent macrophage cell line. Nature 324: 377–389, 1986. 73 Young DC, Wagner K, Griffin JD: Constitutive expression of the granulocyte macrophage colony stimulating factor gene in acute myeloblastic leukemia. J Clin Invest 79: 100–106, 1987. 74 Mitsuyasu RT; Golde DW,: Clinical role of granulocyte macrophage colony stimulating factor. Hematopoietic Growth Factors. Hematol Oncol Clin North Am 3: 411–425, 1989. 75 Hoelzer D, Ganser A, Greker J, et al.: Phase I/II study with GM-CSF in patients with myelodysplastic syndrome. Behring Inst Mitt 83: 134–138, 1988. 76 Antin JH, Smith BR, Holmes W, et al.: Phase I/II study of recombinant human granulocyte macrophage colony stimulating factor in aplastic anemia and myelodysplastic syndrome. Blood 72: 705–713, 1988. 77 Vadhan-Raj S, Keating M, Lemaistre A, et al.: Effects of recombinant human granulocyte macrophage colony stimulating factor in patients with myelodysplastic syndromes. N Engl J Med 317: 1545–1552, 1987. 78 Charache S, Dover G, Smith K, et al.: Treatment of sickle cell anemia with 5-Azacytidine results in increased fetal hemoglobin production and is associated with mandatory hypomethylation of DNA around the γ-δ-β-Globin aene complex. Proc Natl Acad Sci USA 80: 4842–4826, 1983. 79 Koeffler HP: Induction of differentiation of human acute myelogenous leukemia cells: Therapeutic implications. Blood 62: 709–721, 1983. 80 Bollag W: Retinoids and cancer. Cancer Chemother Pharmacol 3: 207–215, 1979. 81 Saffiotti V, Montesano R, Sellakumar AR, et al.: Experimental cancer of the lung. Inhibition by vitamin A of the induction of tracheobronchial squamous metaplasia and squamous cell tumors. Cancer 20: 857–864, 1967. 82 McCue PA, Thomas RS, Schroeder D, et al.: Effects of dietary retinoids upon growth and differentiation of tumors derived from several murine embryonal carcinoma cell lines. Cancer Res 48: 3772–3779, 1988. 83 Meyskens FL, Jr: Clinical trials of retinoids as differentiation inducers. The status of differentiation therapy in cancer. Serono Symposia Publ 45: 349–359, 1988. 84 Stoner CM, Gudas LJ: Mouse cellular retinoic acid binding protein: Cloning, complementary DNA sequence, and messenger RNA expression during the retinoic acid induced differentiation of F9 wild type and RA-3-10 mutant teratocarcinoma cells. Cancer Res 49: 1497–1504, 1989. 85 Takahashi N, Breitman TR: Retinoic acid acylation (retinoylation) of a nuclear protein in the human acute myeloid leukemia cell line, HL60. J Biol Chem 264: 5159–5163, 1989. 86 Flynn PJ Miller WJ, Weisdorf DJ: Retinoic acid treatment of acute promyelocytic leukemia: In vitro and in vivo observations. Blood 62: 1211–1217, 1983. 87 Fontana JA, Rogers JS, Durham JP: The role of 13-cis retinoic acid in the remission induction of a patient with acute promyelocytic leukemia. Cancer 57: 209–217, 1986. 87a Degos C, Chomienne P, Ballerini P, et al.: All-trans-Retinoic acid: A novel differentiation therapy for acute promyelocytic leukemia. Proc Am Assoc Clin Oncol 9: 207, 1990. 88 Clamon G, Chabot GG, Valeriote F, et al.: Phase I study and pharmacokinetics of weekly high dose 13-cis retinoic acid. Cancer Res 45: 1874–1878, 1985. 89 Hoffman SJ, Robinson WA: Use of differentiation inducing agents in the myelodysplastic syndrome and acute nonlymphocytic leukemia. Am J Hematol 28: 124–127, 1988. 90 Clark RE, Ismail SA, Jacobs A, et al.: A randomized trial of 13-cis retinoic acid with or without cytosine arabinoside in patients with the myelodysplastic syndrome. BrJ Haematol 66: 77–83, 1987. 91 Thomsen K. Molin L, Volden G, et al.: 13-cis retinoic acid effective in mycosis fungoides. A report from the Scandinavian Mycosis Funaoides Group. Acta Derm Venereol (stockh) 64: 563–566, 1984. 92 Molin L. Thomsen K. Volden G, et al.: Oral retinoids in mycosis fungoides and Sezary syndrome: A comparison of isotretinoin and etretinate. A study from the Scandinavian Mycosis Fungoides Group. Acta Derm Venereol (stockh) 67: 232–236, 1987. 93 Kessler JF, Jones SE, Levine N, et al.: Isotretinoin and cutaneous helper T cell lymphoma (mycosis fungoides). Arch Dermatol 123: 201–204, 1987. 94 Francis GE, Pinsky CM: Clinical trials of differentiation therapy: Current trials and future prospects. The status of differentiation therapy of cancer. Serono Symposia Publ 45: 349–359, 1988. 95 Lippman SM, Meyskens FL, Jr: Treatment of advanced squamous cell carcinoma of the skin with isotretinoin. Ann Intern Med 107: 499–501, 1987. 96 Prutkin L: The effect of vitamin A acid on hyperkeratinization and the keratoacanthoma. J Invest Dermatol 49: 165–172, 1967. 97 Prutkin L: Antitumor activity of vitamin A acid and fluorouracil used in combination on the skin tumor keratoacanthoma. Cancer Res 33: 128–133, 1973. 98 Epstein JH: All-trans retinoic acid and cutaneous cancers. J Am Acad Dermatol 15: 772–778, 1986. 99 Meyskens FL, Gilmartin E. Alberts DS, et al.: Activity of isotretinoin against squamous cell cancers and preneoplastic lesions. Cancer Treat Rep 66: 1315–1319, 1982. 100 Levine N. Miller RC, Meyskens FL, Jr.: Oral Isotretinoin therapy: Use in a patient with multiple cutaneous squamous cell carcinomas and keratoacanthomas. Arch Dermatol 120: 1215–1217, 1984. 101 Kingston T, Gaskell S, Marks R: The effects of a novel potent oral retinoid (r013-6298) in the treatment of multiple solar keratoses and squamous cell epithelioma. Eur J Cancer Clin Oncol 19: 1201–1205, 1983. 102 Kraemer KH, Digiovanna JJ, Moshell AN, et al.: Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin. N Engl J Med 318: 1633–1637, 1988. 102a Hong WK, Lippman SM, Itri L, et al.: Prevention of second malignant tumors (sMTs) in head and neck cancer with 13-cis-Retinoic acid (13cRA): Placebo-Controlled, double-Blind, randomized trial. Proc Am Assoc Clin Oncol 9: 171, 1990. 103 Meyskens FL, Jr. Surwit ES: Clinical experience with topical tretinoin in the treatment of cervical dysplasia. J Am Acad Dermatol 15: 826–829, 1986. 104 Meyskens FL, Jr, Edwards L, Levine NS: Role of topical tretinoin in melanoma and dysplastic nevi. J Am Acad Dermatol 15: 822–829, 1986. 105 Hong WK, Endicott J, Itri LM, et al.: 13-cis retinoic acid in the treatment of oral leukoplakia. N Engl J Med 315: 1501–1505, 1986. 106 Gouveia J, Mathe G, Hercend T. et al.: Degree of bronchial metaplasia in heavy smokers and its regression after treatment with a retinoid. Lancet 1: 710–712, 1982. 107 Lippman SM, Meyskens FL, Jr: Vitamin A derivatives in the prevention and treatment of human cancer. J Am Coll Nutr 7: 269–284, 1988. 108 Cheson BD, Jasperse DM, Chun HG, et al.: Differentiating agents in the treatment of human malignancies. Cancer Treat Rev 13: 129–145, 1986. 109 Buzaid AC, Garewal HS, Greenberg BR: Management of myelodysplastic syndromes. Am J Med 80: 1149–1157, 1986. 110 Jacobs A: Myelodysplastic syndromes: Pathogenesis, functional abnormalities and clinical implications. J Clin Pathol 38: 1201–1217, 1985. 111 Mosset M, Daniel T, Degos L: Small doses of Ara-C in the treatment of acute myeloid leukaemias. Differentiation of myeloid leukaemia cells? Br J Haematol 51: 125–129, 1982. 112 Castaigne S. Daniel MT, Tilly H, et al.: Does treatment with Ara-C in low dosages cause differentiation of leukaemic cells? Blood 62: 85, 86, 1983. 113 Michalewicz R, Lotem J, Sachs L: Cell differentiation and therapeutic effect of low doses of cytosine arabinoside in human myeloid leukaemia. Leuk Res 8: 783–790, 1984. 114 Wisch JS, Griffin JD, Kufe DW: Response of preleukaemic syndromes to continuous infusion of low dose cytarabine. N Engl J Med 309: 1599–1602, 1983. 115 Tricot G, DeBock R, Dekker AW, et al.: Low dose cytosine arabinoside (ara-C) in myelodysplastic syndromes. Br J Haematol 58: 231–240, 1984. 116 Spiers ASD, Chikkappa G, Lorch CA: Myelodysplastic syndrome: Cytogenetic changes before and after response to low dose Ara-C. Blood 64: 174a, 1984. 117 Weinberg JB, Larrick JW: Receptor mediated monocytoid differentiation of human promyelocytic cells by tumor necrosis factor: Synergistic actions with interferon-γ and 1,25-Dihydroxyvitamin D3. Blood 70: 994–1002. 1987. 118 Takuma T, Takeda K, Konno K: Synergism of tumor necrosis factor and interferon-γ in induction of differentiation of human myeloblastic leukemic ML-1 cells. Biochem Biophys Res Commun 145: 514–521, 1987. 119 Chang EH, Ridge J, Yu Z, et al.: Induction of altered oncogene expression and differentiation of squamous cell carcinoma in vitro. The status of differentiation therapy of cancer. Serono Symposium Publ 45: 63–77, 1988. 120 Katakami Y, Nakao Y, Katakami N, et al.: Cooperative effects of tumor necrosis factor-α and 1,25-Dihydroxyvitamin D3 on growth inhibition, differentiation and c-Myc reduction in human promyelocytic leukemia cell line, HL60. Biochem Biophys Res Commun 152: 1151–1157, 1988. 121 Spremulli EN, Dexter DL: Polar solvents: A novel class of antineoplastic agents. J Clin Oncol 2: 227–241, 1989. 122 Egorin MJ: Clinical trials of polar differentiation agents. The status of differentiation therapy of cancer. Serono Symposia Publ 45: 389–404, 1988. 123 Scher W, Friend C: Breakage of DNA and alterations in folded genomes by inducers of differentiation in Friend erytaroleukemic cells. Cancer Res 38: 841–849, 1978. 124 Crabtree GW, Dexter DL, Stoeckler JD, et al.: Activities of purine metabolizing enzymes in human colon carcinoma cell lines and xenograft tumors. Biochem Pharmacol 30: 793–798, 1981. 125 Dexter DL, Barbosa JA, Calabresi P: N,N-Dimethylformamide induced alteration of cell culture characteristics and loss of tumorigenicity in cultured human colon carcinoma cells. Cancer Res 39: 1020–1025, 1979. 126 Cunh H, Leyland Jones B, Hoth D, et al.: Hexamethylene bisacetamide: A polar-Planar compound entering clinical trials as a differentiating agent. Cancer Treat Rep 70: 991–996, 1986. 127 Walsh TD, Fanucchi MP, Williams L, et al.: Phase I clinical and pharmacokinetic study of hexamethylene bisacetamide (hMBA) by 10 day continuous infusion (cI). Proc Am Assoc Cancer Res 28: 188, 1987. 128 McGuire WP, Rowinsky EK, Ettinger DS et al.: Prolonged infusion of hexamethylene bisacetamide (hMBA): Phase I and pharmacologic study. Proc Am Assoc Cancer Res 28: 193, 1987. 129 O'dwyer PJ, Donehower M, Sigman LM: Phase I trial of N-Methylformamide (nMF, NSC 3051). J Clin Oncol 3: 853–857, 1985. 130 Leith JT, Bliven SF: X-Ray responses of a human colon tumor cell line after exposure to the differentiation inducing agent N-Methylformamide: Concentrations dependence and reversibility characteristics. Int J Radiat Oncol Biol Phys 14: 1231–1237, 1988. 131 Tofilon PJ, Vines CM, Milas L: N-Methylformamide mediated enhancement of in vitro tumor cell chemosensitivity. Cancer Chemother Pharmacol 17: 269–273, 1986. 132 Cordeiro RF, Savarese TM: Role of glutathione depletion in the mechanism of action of N-Methylformamide and N,N-Dimethylformamide in a cultured human colon carcinoma cell line. Cancer Res 46: 1297–1305, 1986. 133 Arundel CM, Bock S, Brook WA, et al.: Radiosensitization of primary human tumor cell cultures by N-Methylformamide. Int J Radiat Oncol Biol Phys 13: 753–757, 1987. 134 Ingber S, Weimann MC, Campagnone N, et al.: Maturation induction and chemosensitization of a human melanoma cell line by N-Methylformamide. Clin Res 33: 453A, 1985. 135 Ferdari LA, Bliven SF, Weimann MC, et al.: Induction of doxorubicin resistance in heterogeneous human colon tumor cells by N-Methylformamide. Cancer Treat Rep 70: 1177–1180, 1986. 136 Weimann M, Alexander P, Calabresi P: Combination differentiation therapy. The status of differentiation therapy of cancer. Serono Symposia Publ 45: 299–314, 1988. 137 Tauer K, Kemeny N, Cheng E, et al.: Phase II trial of N-Methylformamide in patients with advanced colorectal carcinoma. Cancer Treat Rep 70: 813, 814, 1986. 138 Tarella C, Ferrero D, Gallo E, et al.: Induction of differentiation of HL60 cells by dimethylsulfoxide: Evidence for a stochastic model not linked to the cell division cycle. Cancer Res 42: 445–449, 1982. 139 Fuks JZ, Egorin MJ, Aisner J, et al.: Cyclophosphamide and dimethylsulfoxide in the treatment of squamous carcinoma of the lung. Cancer Chemother Pharmacol 6: 117–120, 1981. 140 Sakurai M, Sampi K, Hozumi M: Possible differentiation of human acute myeloblastic leukemia cells by daily and intermittent administration of aclacinomycin-A. Leuk Res 7: 139–143. 1983. 141 Case Jr DC, Boyd M, Bove LG: Phase II trial of aclacinomycin in acute myelogenous leukemia (aML). Proc Am Assoc Cancer Res 26: 697A, 1985. 142 Christman JK, Mendelsohn N. Herzog D. et al.: Effect of 5-Azacytidine on differentiation and DNA methylation in human promyelocytic leukemia cells. Cancer Res 43: 763–769, 1983. 143 Novogrodsky A, Duir A, Ravid A, et al.: Effect of polar organic compounds on leukemic cells: Butyrate induced partial remission of acute myelogenous leukemia in a child. Cancer 51: 9–14, 1983. 144 Miller AA, Kurschel E, Schmidt CG: Clinical and pharmacologic study of sodium butyrate in patients with acute leukemia. Proc Am Assoc Cancer Res 26: 1046, 1985. 145 Leith JT, Hallows KT, Arundel CM, et al.: Changes in x-Ray sensitivity and glutathione content of human colon tumor cells after exposure to the differentiation inducing agent sodium butyrate. Radiat Res 114: 579–588, 1988. 146 Warrell RP, Coonley CJ, Gee TS: Homoharringtonine: An effective new drug for remission induction in refractory nonlymphoblastic leukemia. J Clin Oncol 3: 617–621, 1985. 147 Boyd AW, Sullivan JR: Leukemic cell differentiation in vivo and in vitro: Arrest of proliferation parallels the differentiation induced by the antileukemic drug harringtonine. Blood 63: 384–392, 1984. 148 Ankerst J, Faldt R. Nilsson PG, et al.: Complete remission in a patient with acute myelogenous leukemia treated with leukocyte α-Interferon and cimetidine. Cancer Immunol Immunother 17: 69–71, 1984. 149 Gavosto F, Maiolo AT, Aglietta M, et al.: Treatment with interferon-γ in myelodysplastic syndromes: A pilot study. The status of differentiation therapy of cancer. Serono Symposia Publ 45: 375–388, 1988. 150 Ratain MJ, Golomb RH, Tormey DC, et al.: Treatment of hairy cell leukemia with recombinant interferon-α2. Blood 65: 644–648. 1985. 151 O'dwyer PJ, Cheson BD, Leyland-Jones B, et al.: Deoxycoformycin: An active new drug for indolent lymphomas and hairy cell leukemias. Oncology 2: 17–22, 1988. 152 Piro LD, Carrera CJ, Carson DA, Buetler E: Lasting remission in hairy cell leukemia induced by a single infusion of 2-Chlorodeoxyadenosine. N Engl J Med 322: 1117–1121, 1990. 153 Koeffler HP, Hirji K, Itri L: 1,25-Dihydroxivitamin D3 in vivo and in vitro effects on human preleukemic and leukemic cells. Blood 64 (1): 578A, 1984. 154 Koller Ca, Miller DM: Mithramycin: An effective agent in the blast phase of chronic granulocytic leukemia. Blood 64 (1): # 579, 167a, 1984. 155 Balkmill FR: “ Cytokines in Cancer Therapy.” Oxford: Oxford University Press, 1989, pp 1–241. 156 Hellstrom KE, Hellstrom I: Oncogene associated tumor antigens as targets for immunotherapy. FASEB J 3: 1715–1722, 1989. 157 Kohn DB, Anderson WF, Blaese RM: Gene therapy for genetic diseases. Cancer Invest 7: 179–192, 1989. 158 Huber BE: Therapeutic opportunities involving cellular oncogsenes: Novel approaches fostered by biotechnology. FASEB J 3: 5–13, 1989. 159 Jimenez JJ, Yunis AA: Tumor cell rejection through terminal cell differentiation. Science 238: 1278–1280, 1987. 160 Moscow JA, Cowan KH: Multidrug resistance. JNCI 80: 14–20. 1988. 161 DeLisi C: Computers in molecular biology: Current applications and emerging trends. Science 240: 47–52, 1988. 162 Fleischman SH: Rational drug design using supercomputers. Scientific Computing Automation 5 (7): 23–26, 1989. Volume19, Issue21991Pages 71-83 ReferencesRelatedInformation
Publication Year: 1991
Publication Date: 1991-01-01
Language: en
Type: review
Indexed In: ['crossref', 'pubmed']
Access and Citation
Cited By Count: 1
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot